Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | RXRG | P48443 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15388527 | 0.86 | CYP4F2 (0.41) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL29048976 | 0.83 | ALDH1A1 (0.43) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL24142066 | 0.78 | CYP4F2 (0.41) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL19523845 | 0.78 | CYP4F2 (0.39) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL24456419 | 0.75 | KDM5B (0.36) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL3401227 | 0.74 | ALDH1A1 (0.39) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL16132481 | 0.73 | CYP4F2 (0.49) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL26986555 | 0.73 | ALDH1A1 (0.39) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL24497787 | 0.72 | CYP4F2 (0.48) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL19277096 | 0.71 | ALDH1A1 (0.37) | CYP4F2CYP4A11ALDH1A1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295166-A1 | ATR INHIBITORS AND USES THEREOF | ANTENGENE DISCOVERY LIMITED (CN) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295166-A1 | ATR INHIBITORS AND USES THEREOF | ATR, CHEK1, CHEK2 | CYP4F2 4245/4885CYP4A11 4459/4885ALDH1A1 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.